PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22144664-13	2012	Our findings indicate that the MEK-ERK pathway is a potential target for EGFR-overexpressing CCC and indicate that selumetinib and erlotinib are worth exploring as therapeutic agents for CCC.	AZD 6244	115-126	epidermal growth factor receptor	Mus musculus	73-77	
32888253-3	2020	The present study aimed to use proteomic methods to probe into the role of the EGF-EGFR-angiogenesis axis in the tumorigenesis of glioma and access the therapeutic efficacy of selumetinib on glioma.	AZD 6244	176-187	epidermal growth factor receptor	Mus musculus	83-87	
34856074-7	2022	Cell lines treated with trametinib or AZD6244 in combination with AZD0424 had reduced EGFR, FAK and SRC compensatory activation, and, cell viability was synergistically inhibited.	AZD 6244	38-45	epidermal growth factor receptor	Mus musculus	86-90	
32888253-12	2020	Selumetinib treatment showed tumor reduction effect in EGFR-positive glioblastoma xenograft mouse model.	AZD 6244	0-11	epidermal growth factor receptor	Mus musculus	55-59	
32888253-14	2020	Selumetinib could target the EGFR pathway and possibly improve the prognosis of EGFR-positive glioma.	AZD 6244	0-11	epidermal growth factor receptor	Mus musculus	29-33	
32888253-14	2020	Selumetinib could target the EGFR pathway and possibly improve the prognosis of EGFR-positive glioma.	AZD 6244	0-11	epidermal growth factor receptor	Mus musculus	80-84